GLP1R and sarcopenia: Meanwhile, GLP-1 receptor agonists and DPP-IV inhibitors (incretin-based agents, used by 3/12 participants in Baasch-Skytte et al., 2021) can induce appetite suppression and weight loss, potentially exacerbating sarcopenia, a risk that may reduce mitochondrial density and blunt exercise’s effects on OXPHOS (Lecce et al., 2025), though this was not controlled for in analyses.